Evidence map›Paper›PMID 27820930›Full record

Trial reportCerebrovascular diseases (Basel, Switzerland)2017

Is There Benefit from Stenting on Cognitive Function in Intracranial Atherosclerosis?

Tanya N Turan, Alison Smock, George Cotsonis, David Bachman, Sami Al Kasab, Michael J Lynn, Azhar Nizham, Collin P Derdeyn, David Fiorella, Scott Janis and 4 more

Open access · bronzeAbstract readComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in Cerebrovascular diseases (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Poststroke Montreal Cognitive Assessment and Recurrent Stroke in Patients With Symptomatic Intracranial Atherosclerosis.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2020
    Article
  6. Article
  7. Intracranial atherosclerotic disease.Neurobiology of disease · 2019
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Tanya N TuranMedical University of South Carolina, Charleston, S.C., USA.
Alison Smock
George Cotsonis
David Bachman
Sami Al Kasab
Michael J Lynn
Azhar Nizham
Collin P Derdeyn
David Fiorella
Scott Janis
Bethany Lane
Jean Montgomery
Marc I Chimowitz
SAMMPRIS Investigators
Emory University · USMedical University of South Carolina · USNational Institute of Neurological Disorders and Stroke · USState University of New York · USUniversity of Iowa Hospitals and Clinics · US

Funding

SAMMPRIS (Stenting vs. Aggressive Medical Management for Preventing . . .U01NS058728 · NINDS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI CHIMOWITZ, MARC IVOR · 2008 to 2011
$20.0M
Characterization of Intracranial Atherosclerotic Stenosis Using HR MRIK23NS069668 · NINDS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI TURAN, TANYA N · 2011 to 2015
$903k
NINDS NIH HHS K23 NS069668NINDS NIH HHS U01 NS058728
6 · The paper itself

Abstract

backgroundRevascularization of stenotic cerebral arteries is hypothesized to improve cognition by increasing cerebral perfusion.

aimsWe compared cognition impairment among patients treated with percutaneous angioplasty and stenting (PTAS) and aggressive medical management (AMM) versus AMM alone in the Stenting versus Aggressive Medical Therapy for Intracranial Arterial Stenosis (SAMMPRIS) Trial.

methodsIn SAMMPRIS, 451 patients with recent transient ischemic attack or stroke attributed to 70-99% intracranial stenosis were randomized to PTAS plus AMM or AMM alone. Patients who had stroke as the qualifying event with National Institutes of Health Stroke Scale indicating aphasia or neglect were excluded from these analyses. Patients with a cerebrovascular event (ischemic stroke, cerebral infarct with temporary signs or intracranial hemorrhage) during follow-up were excluded from follow-up visit analyses. The Montreal Cognitive Assessment (MoCA) score was used to assess cognition impairment at baseline, 4 months, 12 months and closeout. Cognitive impairment was defined as MoCA <26. Mean MoCA scores and the percentage of patients with cognitive impairment were compared between treatment groups at each time point using t tests and chi-square tests. Differences in MoCA mean at baseline and follow-up time points were compared using mixed model repeated measures ANOVA and Tukey-Kramer tests.

resultsThere were no significant differences between the treatment groups for mean MoCA at any time point. Mean MoCA scores improved in both groups. The percentage of patients with cognitive impairment in the AMM versus PTAS groups was not significantly different at any time point.

conclusionsRevascularization with PTAS showed no improvement in cognitive impairment over AMM alone among patients who did not have recurrent cerebrovascular events during follow-up.

Indexed as

CognitionStentsAngioplastyCardiovascular AgentsChi-Square DistributionCognition DisordersHumansIntracranial ArteriosclerosisNeuropsychological TestsRecovery of FunctionRisk FactorsTime FactorsTreatment OutcomeCardiovascular Agents

Identifiers

PMID27820930
PMCPMC5319918
OpenAlexW2556189086

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.